The World Health Organization (WHO) has listed depression as a leading cause of disability worldwide and a major contributor to the overall global burden of disease. Unfortunately, traditional treatments…
Ketamine
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
An exciting point in the markets for Psychedelics! The technicals currently indicate money returning to the psychedelics sector. Now we just look for charts that are about to breakout,…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Interest in the psychedelic market is as high as Matt Gaetz and Joel Greenberg on a night out, but the accompanying FOMO has the potential to muddy the market,…
The psychedelics space is one of the hottest investment trips in the public markets today. Embryonic, wide open to possibility and with mounting scientific evidence of psychedelics’ healing properties,…
Braxia Scientific (BRAX.C) announced they will be conducting a randomized clinical trial that will involve giving patients multiple doses of psilocybin. Braxia says this is Canada’s first psilocybin trial…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Awakn Life Sciences (AWKN.NE) announced it has received ethical approval to conduct the first-ever study of the effects of ketamine on gambling addiction. Awakn has begun to recruit patients…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…